Goldman Sachs’s Aimmune Therapeutics AIMT Stock Holding History

Goldman Sachs’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-55,000	Closed	-$919K	–	5646
2020 Q2	$919K	Sell	55,000 -25,600	-32%	-$435K	﹤0.01%	4011
2020 Q1	$1.16M	Buy	80,600 +50,600	+169%	+$1.29M	﹤0.01%	3647
2019 Q4	$1M	Hold	30,000	–	–	﹤0.01%	4122
2019 Q3	$628K	Buy	+30,000	New	+$612K	﹤0.01%	4331
2017 Q4	–	Sell	-22,000	Closed	-$545K	–	6808
2017 Q3	$545K	Buy	+22,000	New	+$474K	﹤0.01%	5033

Goldman Sachs's AIMT Position: Q4 2020 in Review

Goldman Sachs sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,201,089 shares — an estimated $75.8M sold.

Goldman Sachs first reported a position in AIMT in Q3 2015 and held it in 18 quarters. The position peaked at $75.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Goldman Sachs reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Goldman Sachs sold 2,201,089 Aimmune Therapeutics shares in Q4 2020, an estimated $75.8M.
Goldman Sachs first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 18 quarters.
Goldman Sachs's Aimmune Therapeutics position peaked at $75.8M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.